Search Clinical Trials
Our researchers are currently in need of adult and pediatric study participants to help us pursue better treatments and cures. Participants may receive medical evaluations and procedures, study medication, disease-related education and possible financial compensation for time, travel and participation.
Select a Condition or Specialty
- Allergy
- Alpha-1 Antitrypsin Deficiency
- Asthma
- Cardiology
- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19 (Coronavirus)
- Cystic Fibrosis
- Eczema (Atopic Dermatitis)
- Environmental & Occupational Health
- Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Food Allergy
- Gastroenterology
- Idiopathic Pulmonary Fibrosis (IPF)
- Interstitial Lung Disease (Pulmonary Fibrosis)
- Lung Cancer
- Oncology
- Pulmonary Hypertension (PH)
- Respiratory (Pulmonary)
- Rheumatology
- Sarcoidosis
All Clinical Trials
Possible New Inhaled Treatment Option for PH with ILD
Pulmonary hypertension (PH), or high blood pressure in the lungs, can often develop in those who have interstitial lung disease (ILD). Treatments for this combination of diseases, called PH-ILD, to try and improve quality of life for people with both conditions are currently being evaluated.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Six visits over approximately 52 weeks, with two initial visits for enrollment and then visits at weeks 8, 16, 24 and 52.
Differences in the Pulmonary Artery of People with Pulmonary Hypertension
Pulmonary hypertension and pulmonary arterial hypertension are two conditions that can cause increased blood pressure within the lungs. The differences between the two conditions on a cellular level are not well understood, and researchers are evaluating cell samples from people that are undergoing a right heart catheterization to learn more about these two diseases and improve future care.
- Gender
- Any
- Ages
- 18+
- Compensation
- Not Provided
- Time Required
- One visit to review and sign consent before scheduled procedure and three follow-up phone calls (once a year for three years).
Effects of Keto Diet in People with HFpEF
The keto diet has helped many people lose weight and improve their overall health. Researchers are investigating if it can also benefit people with a specific type of heart failure.
- Gender
- Any
- Ages
- 21-79
- Compensation
- Provided
- Time Required
- 12-week post-study testing is complete. There will be an option to enroll in a 12-week extension arm (for a total of 24 weeks). Primary study commitment will involve a total of 9 visits
New Trial Medication for Pulmonary Arterial Hypertension
By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Up to 42 months
Pulmonary Arterial Hypertension & increased dose of Opsumit
The UNISUS study will compare the effectiveness and safety of a higher dose of an investigational medication called Opsumit to a lower dose in people with pulmonary arterial hypertension (PAH). The results of the UNISUS Study will provide more information about the investigational medication’s effectiveness and safety when it is given as a higher dose to adults with PAH.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.
Adult Trials
Possible New Inhaled Treatment Option for PH with ILD
Pulmonary hypertension (PH), or high blood pressure in the lungs, can often develop in those who have interstitial lung disease (ILD). Treatments for this combination of diseases, called PH-ILD, to try and improve quality of life for people with both conditions are currently being evaluated.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Six visits over approximately 52 weeks, with two initial visits for enrollment and then visits at weeks 8, 16, 24 and 52.
New Trial Medication for Pulmonary Arterial Hypertension
By adding a new investigational Pulmonary Arterial Hypertension (PAH) medication to your current therapy, you could experience relaxed and widened artery walls.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Up to 42 months
Pulmonary Arterial Hypertension & increased dose of Opsumit
The UNISUS study will compare the effectiveness and safety of a higher dose of an investigational medication called Opsumit to a lower dose in people with pulmonary arterial hypertension (PAH). The results of the UNISUS Study will provide more information about the investigational medication’s effectiveness and safety when it is given as a higher dose to adults with PAH.
- Gender
- Any
- Ages
- 18+
- Compensation
- Provided
- Time Required
- Up to 4 years. Year 1: monthly visits. Year 2: visits every three months. Years 3-4: visits every six months.
Pediatric Trials
Healthy Participant Trials
Possible New Inhaled Treatment Option for PH with ILD
Pulmonary hypertension (PH), or high blood pressure in the lungs, can often develop in those who have interstitial lung disease (ILD). Treatments for this combination of diseases, called PH-ILD, to try and improve quality of life for people with both conditions are currently being evaluated.
- Gender
- Any
- Ages
- 18-75
- Compensation
- Provided
- Time Required
- Six visits over approximately 52 weeks, with two initial visits for enrollment and then visits at weeks 8, 16, 24 and 52.